Clearside Biomedical

CLSDPhase 3

Clearside Biomedical is revolutionizing the treatment of sight-threatening retinal diseases by developing and commercializing therapies delivered through its proprietary suprachoroidal space (SCS) injection platform. The company has validated its technology with the FDA-approved product XIPERE® for uveitic macular edema and is advancing its lead candidate, CLS-AX (axitinib), into Phase 3 trials for wet AMD. Clearside leverages strategic partnerships to expand its pipeline and commercial reach, positioning itself as the leader in targeted ocular drug delivery.

Market Cap

$2.1M

Focus

Drug DeliverySmall Molecules

CLSD · Stock Price

USD 0.5634.84 (-98.41%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Suprachoroidal Space (SCS) injection platform using the SCS Microinjector® for targeted, compartmentalized, in-office delivery of therapies to the back of the eye.

Pipeline Snapshot

13 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
4mg CLS-TA Suprachoriodal Injection + Sham Procedure	Uveitis	Phase 3
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin	Macular Edema	Phase 3
4 mg CLS-TA Suprachoriodal Injection	Uveitis	Phase 3
suprachoroidal CLS-TA + suprachoroidal sham + IVT aflibercept	Macular Edema	Phase 3
CLS-AX + Aflibercept	Neovascular Age-related Macular Degeneration	Phase 2

Opportunities

The primary growth opportunity is the successful development and commercialization of CLS-AX in the multi-billion dollar wet AMD market.

Additional opportunities lie in expanding the use of the SCS platform through new partnerships for other retinal diseases (e.g., diabetic macular edema, retinal vein occlusion) and therapeutic modalities like gene therapy, creating a diversified revenue stream from royalties, milestones, and proprietary products.

Risk Factors

Key risks include clinical failure of CLS-AX in Phase 3 trials, challenges in achieving market adoption against established anti-VEGF therapies, future dilution from necessary capital raises, and potential competition from alternative long-acting delivery technologies or new SCS access methods.

Competitive Landscape

Clearside competes with established anti-VEGF therapies (Eylea, Vabysmo) in wet AMD and other ocular drug delivery platforms (implants, port systems). Its main differentiation is its first-mover, FDA-validated suprachoroidal delivery platform, which offers targeted, compartmentalized dosing with a favorable safety profile and in-office administration.